First Light Asset Management LLC Has $31.39 Million Stock Holdings in AtriCure, Inc. $ATRC

First Light Asset Management LLC decreased its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC) by 12.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 890,362 shares of the medical device company’s stock after selling 124,808 shares during the period. AtriCure comprises 3.0% of First Light Asset Management LLC’s portfolio, making the stock its 12th biggest holding. First Light Asset Management LLC’s holdings in AtriCure were worth $31,385,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in ATRC. Wellington Management Group LLP grew its stake in shares of AtriCure by 8.1% in the 3rd quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company’s stock valued at $151,296,000 after purchasing an additional 322,818 shares during the period. Hood River Capital Management LLC lifted its position in shares of AtriCure by 2.1% during the 2nd quarter. Hood River Capital Management LLC now owns 3,061,059 shares of the medical device company’s stock worth $100,311,000 after buying an additional 61,852 shares during the period. Neuberger Berman Group LLC lifted its position in shares of AtriCure by 0.3% during the 2nd quarter. Neuberger Berman Group LLC now owns 1,189,739 shares of the medical device company’s stock worth $38,969,000 after buying an additional 3,674 shares during the period. Geode Capital Management LLC boosted its stake in AtriCure by 1.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,181,737 shares of the medical device company’s stock valued at $38,731,000 after buying an additional 14,577 shares in the last quarter. Finally, Marshall Wace LLP boosted its stake in AtriCure by 1.1% in the 2nd quarter. Marshall Wace LLP now owns 1,005,248 shares of the medical device company’s stock valued at $32,942,000 after buying an additional 11,155 shares in the last quarter. 99.11% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Wall Street Zen upgraded AtriCure from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 21st. Needham & Company LLC restated a “buy” rating and issued a $45.00 target price on shares of AtriCure in a research note on Thursday, February 12th. Oppenheimer lowered shares of AtriCure from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AtriCure in a research report on Wednesday, January 21st. Finally, Zacks Research downgraded shares of AtriCure from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 18th. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.43.

AtriCure Stock Performance

Shares of NASDAQ:ATRC opened at $29.84 on Monday. The business has a fifty day moving average of $35.25 and a 200-day moving average of $36.10. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.99 and a current ratio of 3.96. AtriCure, Inc. has a twelve month low of $28.29 and a twelve month high of $43.18. The firm has a market cap of $1.49 billion, a PE ratio of -124.33 and a beta of 1.42.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Tuesday, February 17th. The medical device company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.10. AtriCure had a negative net margin of 2.14% and a negative return on equity of 1.15%. The business had revenue of $140.50 million for the quarter, compared to the consensus estimate of $140.50 million. During the same quarter in the prior year, the company earned ($0.33) EPS. The firm’s quarterly revenue was up 13.1% on a year-over-year basis. On average, equities research analysts predict that AtriCure, Inc. will post -0.6 EPS for the current fiscal year.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.